… ProQR Announces Clinical Data Presentations and Investor & … the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … 27 Noreen Henig, M.D., Chief Development Officer of ProQR and John P. Clancy, M.D., principal investigator, …
… ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory … LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … codons,” said Daniel de Boer, chief executive officer of ProQR. "We welcome Dr. Yu to our scientific advisory board, …
… ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, chief executive officer of ProQR. “Both sepofarsen for LCA10, the most common cause of …
… ProQR Announces Presentations on Programs in Ophthalmology at … LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … II Presentation at OIS Retina Daniel de Boer, CEO of ProQR, will give a presentation highlighting the company’s …
… ProQR Announces Presentations at the European Oligonucleotide … and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Peter Adamson, PhD, SVP Ophthalmology Science of ProQR Presentation : Thursday, November 8 at 14:15 - …
… ProQR Achieves Successful Defense of New Challenge to its … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … the European Patent Office (EPO) by a strawman against ProQR’s granted patent EP 3 507 366 B1 , which relates to …
… ProQR Announces Annual Meeting of Shareholders to be Held May … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
… ProQR Announces Fourth Quarter and Full Year 2021 Operating … & CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … in Q2,” said Daniel A. de Boer, Founder and CEO of ProQR. “Based on the previous data we have reported, we …
Extends ProQR’s cash runway into 2023ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 (GLOBE NEWSWIRE) --
… ProQR Announces Fourth Quarter and Full Year 2020 Operating … & CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … last month,” said Daniel A. de Boer, Founder and CEO of ProQR. “On the basis of this performance, we begin 2021 in a …